Literature DB >> 16783861

Low serum levels of DHEAS in untreated polymyalgia rheumatica/giant cell arteritis.

Javier Narváez1, Berta Bernad, Cesar Díaz Torné, Jaime Vilaseca Momplet, Jordi Zaragoza Montpel, Joan M Nolla, José Valverde-García.   

Abstract

OBJECTIVE: To address a controversy regarding the existence of a relative adrenal hypofunction in patients with untreated polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) we evaluated baseline serum levels of ACTH, cortisol, and DHEAS in a cohort of patients with recent onset PMR/GCA not previously treated with glucocorticoids, in comparison with healthy controls. Possible correlations between baseline DHEAS levels and laboratory measures of disease activity were also explored.
METHODS: Basal serum levels of these hormones were prospectively investigated in 25 patients with active untreated disease and compared with those of 25 age- and sex-matched control subjects.
RESULTS: Of the 25 patients, 19 had isolated PMR and 6 had biopsy-proven GCA + PMR. Basal levels of cortisol and ACTH in PMR/GCA patients did not differ from control subjects; in relation to inflammatory status, lower than expected basal production of cortisol was observed in active untreated PMR/GCA. Baseline serum DHEAS levels were significantly lower in all patients compared with controls. In these patients, a significant correlation was found between baseline DHEAS values and laboratory measures of disease activity. The percentage of DHEAS reduction and the severity of inflammatory response were higher in women than in men.
CONCLUSION: Patients with PMR/GCA with new-onset active disease before steroid treatment have inappropriately normal cortisol levels regarding the ongoing inflammation, and significantly lower levels of DHEAS compared to the age- and sex-matched healthy control subjects. These data support the existence of a relative adrenal hypofunction in PMR and GCA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16783861

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

Review 1.  Advances and challenges in the diagnosis and treatment of polymyalgia rheumatica.

Authors:  Tanaz A Kermani; Kenneth J Warrington
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-02       Impact factor: 5.346

2.  The cortisol:C-reactive protein ratio and negative affect reactivity in depressed adults.

Authors:  Edward C Suarez; John S Sundy
Journal:  Health Psychol       Date:  2017-06-26       Impact factor: 4.267

3.  A case of apoplectic lymphocytic hypophysitis complicated by polymyalgia rheumatica.

Authors:  Yasuko Tanaka; Tomohito Hirao; Keisuke Tsutsumi; Taiichiro Miyashita; Yasumori Izumi; Yumi Mihara; Masahiro Ito; Hiroshi Baba; Kiysohi Migita
Journal:  Rheumatol Int       Date:  2010-06-01       Impact factor: 2.631

4.  Depressogenic vulnerability and gender-specific patterns of neuro-immune dysregulation: What the ratio of cortisol to C-reactive protein can tell us about loss of normal regulatory control.

Authors:  Edward C Suarez; John S Sundy; Alaattin Erkanli
Journal:  Brain Behav Immun       Date:  2014-09-18       Impact factor: 7.217

5.  Activity of the neuroendocrine axes in patients with polymyalgia rheumatica before and after TNF-α blocking etanercept treatment.

Authors:  Frederik Flindt Kreiner; Henrik Galbo
Journal:  Arthritis Res Ther       Date:  2012-08-15       Impact factor: 5.156

Review 6.  Circadian rhythms in rheumatology--a glucocorticoid perspective.

Authors:  Cornelia M Spies; Rainer H Straub; Maurizio Cutolo; Frank Buttgereit
Journal:  Arthritis Res Ther       Date:  2014-11-13       Impact factor: 5.156

7.  Autoimmune Diseases in Patients with Cushing's Syndrome after Resolution of Hypercortisolism: Case Reports and Literature Review.

Authors:  Luigi Petramala; Federica Olmati; Maria Gabriella Conforti; Antonio Concistré; Valeria Bisogni; Nikita Alfieri; Gino Iannucci; Giorgio de Toma; Claudio Letizia
Journal:  Int J Endocrinol       Date:  2018-12-18       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.